Pfizer Inc.

NYSE:PFE  
52.77
-1.28 (-2.37%)
5:00:57 PM EDT: $52.60 -0.17 (-0.32%)
Products, Strategic Combinations

Codex Dna Inc - On Dec 22, 2021, Co Entered Into Research Collaboration And License Agreement With Pfizer Inc

Published: 12/29/2021 13:38 GMT
Pfizer Inc. (PFE) - Codex Dna Inc - on Dec 22, 2021, Co Entered Into Research Collaboration and License Agreement With Pfizer Inc.codex Dna Inc - Co, Pfizer Agreed to Collaborate to Develop Improvements to Co’s Existing Proprietary Bioxp Platform.
Codex Dna Inc - Under Agreement, Pfizer to Make Upfront Payment to Co of $8 Million.
Codex Dna - If Co Meets Certain Milestones, Co Will Be Eligible to Get Additional $10 Million in Payments From Pfizer Related to Conduct of Research and Development Program.
Codex Dna Inc - Pfizer Has Agreed to Pay Co Up to $60 Million in Sales Milestones for Products (other Than Exclusive Products).
Codex Dna Inc - Pfizer Has Agreed to Pay Co Up to Up to $180 Million in Sales Milestones for Exclusive Products.
Codex Dna - Pfizer to Make Milestone Payments to Co With Each Product Being Eligible for Payments Up to $35 Million.
Codex Dna - Provided Agreement Remains in Place, Pfizer Will Pay Escalating Royalties From Low to Mid-fraction of One Percent of Net Sales of Products.
Codex Dna - Pfizer to Make Milestone Payments to Co With First Exclusive Product in Each Exclusive Field Being Eligible for Payment of Up to $55 Million.